Vandetanib Plus Docetaxel Versus Docetaxel As Second-line Treatment For Patients With Advanced Non-small-cell Lung Cancer (ZODIAC): A Double-blind, Randomised, Phase 3 Trial
Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada, Bruce E Johnson
Twitter
Facebook
LinkedIn
Email